# Bioventus Inc. (BVS) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $14.07, market value $961 million.

## Valuation
- **P/E (trailing): 18.0×** (5-yr avg 22.5×, 3-yr avg 22.5×). Bioventus Inc. trades at 18.0× trailing earnings, close to its own five-year average of 22.5×. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 15.3×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.10**. A PEG of 0.10 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 1.7×**. Each dollar of revenue is priced at 1.7×.
- **Price / book: 4.2×**. The shares trade at 4.2× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 11.6×**. Enterprise value is 11.6× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Free-cash-flow yield: 9.8%** (5-yr avg 2.8%). Free cash flow equals 9.8% of the market value, above its five-year average of 2.8%, so the shares are cheaper on cash than they have usually been. Above 5% is generally attractive.
- **Earnings yield: 5.5%**. The inverse of the P/E: 5.5% of the price is earned each year.

## Profitability
- **Gross margin: 68.7%**. Bioventus Inc. keeps 68.7% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 10.0%**. 10.0% of revenue is left after running the business.
- **Net margin: 4.0%**. 4.0% of each dollar of sales reaches the bottom line.
- **Return on equity: 12.3%**. 12.3% on shareholders' equity is solid.
- **Return on invested capital: 10.8%**. Return on all capital, debt included, is 10.8%.
- **Return on assets: 8.0%**. Each dollar of assets produces 8.0% of profit.

## Growth
- **Revenue growth (1 yr): -0.9%** (3-yr 3.5%/yr, 5-yr 12.1%/yr). Revenue fell 0.9% over the last year, against 12.1% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 158.9%**. Earnings per share rose 158.9%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Debt to equity: 1.60**. Debt is 1.60 times equity, a leveraged balance sheet that needs steady cash flow to service.
- **Net debt / EBITDA: 2.3×**. It would take 2.3 years of operating earnings to repay net borrowings, within the comfortable range.
- **Altman Z-score: 2.74**. A Z-score of 2.74 is in the grey zone; not distressed, not clearly safe.
- **Piotroski F-score: 7/9**. 7 of 9 fundamental checks pass: strong and improving financials.

## Dividends
- **Dividend: none**. Bioventus Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (5 analysts). 5 analysts cover Bioventus Inc.; the consensus is strong_buy, with an average price target of $17.60 (+25% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 98.2%** (YTD 89.1%, 3-mo 55.6%). The shares are up 98.2% over twelve months including dividends.
- **From 52-week high: -11.5%** (124.9% above the low). Trading 11% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 56**. An RSI of 56 is neutral.
- **Beta (1 yr): 0.77** (volatility 51%). Beta of 0.77 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=BVS · Page: https://foliofundamentals.com/stocks/bvs

Not investment advice.